PD-L1 expression detected by immunohistochemistry (IHC) in tumor tissue has been used as a predictive biomarker for therapeutic response to PD-1/PD-L1 blockade treatment in various cancers such as non-small cell lung cancer (NSCLC), [1,2]. Here, CD274 is linked to non-small cell lung carcinoma.